Company intelligence / Profile preview
Manistee Therapeutics, Inc.
Newton, Massachusetts, United Statesmanisteetx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Manistee Therapeutics is developing a novel sublingual small molecule therapy targeting PAK4 for the treatment of migraine. Their lead program, MTX-101, is currently in Phase 2 clinical trials. The company’s approach originated from serendipitous scientific observations and aims to provide new options for migraine management based on dedicated research and clinical study[1][2][6].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules[1]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Manistee Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Manistee Therapeutics, Inc..